Asia Pacific Epigenetics Market

The Asia Pacific epigenetics market is projected to reach USD 0.97 billion by 2030 from USD 0.49 billion in 2025, at a CAGR of 14.6% during the forecast period. Major factors driving growth in the Asia Pacific market are the development of the regional biotechnology and pharmaceutical industries and public investments in precision medicine and genomics infrastructure in the region's key countries.

The Asia Pacific epigenetics market is competitive. Prominent players in the Asia Pacific epigenetics market are Thermo Fisher Scientific, Inc. (US), Merck KGaA (Germany), Illumina, Inc. (US), Danaher Corporation (US), and Agilent Technologies, Inc. (US), among others.

To know about the assumptions considered for the study download the pdf brochure

In October 2024, the Agency for Science, Technology and Research (US) and Macrogen, Inc. (South Korea) collaborated with PacBio to launch a state-of-the-art sequencing lab in Singapore to advance genomics innovation in Asia. The facility will leverage PacBio's Revio system to support research in human health, biodiversity, and precision medicine, establishing Singapore as a hub for high-throughput long-read and short-read sequencing technologies. In May 2024, QIAGEN launched the QIAseq Multimodal DNA/RNA Library Kit, enabling seamless preparation of DNA and RNA libraries for next-generation sequencing (NGS), including whole-genome sequencing (WGS) and whole transcriptome sequencing (WTS).   

Thermo Fisher Scientific Inc. is the leader in the Asia Pacific epigenetics market. Its wide range of products, covering sample preparation, nucleic acid workflows, qPCR, and sequencing-compatible solutions, drives strong demand for its methylation and chromatin consumables. The company has a broad reach across major Asia-Pacific countries, supported by a well-established distribution and service network.    

Illumina, Inc. is a key player in the Asia-Pacific epigenetics market, largely because many methylation and chromatin studies run on Illumina sequencing workflows at scale. The company has a strong Asia-Pacific presence. Illumina covers epigenetics on the workflow side with specialized products such as the TruSeq DNA Methylation library prep for WGBS and the Infinium MethylationEPIC v2.0 array for high-throughput methylation profiling. For downstream requirements, Illumina's DRAGEN methylation pipeline supports users in performing methylation-aware alignment, a method that is efficient for large-cohort studies and multi-site projects. These capabilities have strengthened Illumina's market position.   

Merck KGaA is a major player in the Asia Pacific epigenetics market, supported by its broad portfolio of antibodies, chromatin biology reagents, enzymes, and epigenetics assay kits used across ChIP/CUT&Tag and methylation-linked workflows. Its strong distribution and technical support network across Asia Pacific also makes it a reliable, repeat supplier for universities, research institutes, CROs, and biopharma discovery end users conducting epigenomics studies at scale.

Market Ranking

The Asia Pacific epigenetics market is competitive, with leading suppliers holding share through broad workflow coverage, a strong installed base, and reliable local supply across multiple countries. Illumina remains a leading player because its sequencing platforms are widely used across major genomics centers and service labs in China, Japan, South Korea, and Australia, driving high-throughput epigenome profiling. Thermo Fisher Scientific is a strong player with an end-to-end portfolio for methylation and chromatin workflows, supported by a wide distribution reach and repeat consumables demand across academic, CRO, and biopharma labs. Merck KGaA is a prominent challenger, backed by its extensive range of validated antibodies, chromatin reagents, and epigenetics assay kits, which are frequently purchased by end users for routine epigenomics workflows across the region.  

Related Reports:

Asia Pacific Epigenetics Market by Offering [Enzymes, Kits & Reagents, Software, Services], Method [DNA Methylation, Histone Modification], Technique [NGS, PCR], Application [Oncology, Immunology, Developmental Biology], End User - Forecast to 2030

Contact:
Mr. Rohan Salgarkar
MarketsandMarkets™ INC.
1615 South Congress Ave.
Suite 103, Delray Beach, FL 33445
USA: 1-888-600-6441
sales@marketsandmarkets.com